GlassScriptPhysician profile
Juan C Rodriguez
NPI 1518539949
$986.73
in general payments reported to CMS, 2019-2025
23 companies · $75.21 in 2025
The $75.21 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $87.91 · 2022: $267 · 2023: $494 · 2024: $62.77 · 2025: $75.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.74 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $161.65 | 2021-2022 | |
| Astellas Pharma US INC | $104.80 | 2023 | Myrbetriq |
| Integra Lifesciences Corporation | $77.75 | 2024-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Insulet Corporation | $69.82 | 2022 | |
| Exact Sciences Corporation | $67.67 | 2023 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $66.64 | 2023 | |
| Convatec INC. | $64.87 | 2021-2022 | |
| Abbvie INC. | $64.48 | 2023 | |
| Myriad Genetic Laboratories, INC. | $40.74 | 2023 | Prolaris |
| Lilly USA, LLC | $25.37 | 2023 | Jardiance |
| Merck Sharp & Dohme LLC | $24.92 | 2021 | |
| Motiva USA, LLC | $22.43 | 2025 | |
| Sumitomo Pharma America, INC. | $20.96 | 2023 | Gemtesa |
| Tolmar, INC. | $20.76 | 2023 | |
| Medtronic, INC. | $19.47 | 2024 | Vanta Adaptivestim |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $18.67 | 2023 | Tirosint, Licart |
| Amgen INC. | $18.41 | 2023 | Otezla, Repatha |
| Tolmar Pharmaceuticals, INC. | $18.34 | 2022 | |
| Solventum Corporation | $18.33 | 2024 | Prevena |
| Astrazeneca Pharmaceuticals LP | $16.84 | 2023 | Wainua |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.40 | 2022 | |
| Coloplast Corp | $14.58 | 2023 | Speedicath |
| Angiodynamics, INC. | $13.83 | 2023 | Nanoknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.